For many wheelchair users, the chance to stand and walk has been limited to rehabilitation clinics, under the watch of therapists and with crutches or a walker for balance. That changed in August 2026, when the United States Food and Drug Administration cleared Eve, a personal self-balancing exoskeleton built by the French company Wandercraft, for eligible adults living with spinal cord injuries. Eve is described as the first self-balancing personal exoskeleton cleared for use outside a clinic. It uses motors and sensors to keep the wearer upright automatically, so eligible users who can operate its remote control can stand, walk, bend and turn hands-free, and use their hands for everyday tasks. The device was commercially launched in the United States on September 17, 2026. It builds on Wandercraft’s earlier rehabilitation exoskeleton, Atalante X, which is used in more than 150 rehabilitation and research centres around the world. Users steer it with a small handheld controller, and the device adjusts its balance with every step.
What the Evidence Shows
The clearance comes with clear limits, and the company is careful to state them. Eve is designed for use on level indoor surfaces and level outdoor areas immediately next to a building, such as patios and terraces, and always under the supervision of a specially trained companion. It is meant to complement a wheelchair, not replace it, and every user needs a prescription, a clinical assessment, fitting and training before taking one home. Eligibility is not restricted by the level of spinal cord injury, but depends on the person being able to operate the handheld controller safely and having no medical reason not to use it. The clearance was supported by a three-site clinical trial in New York and New Jersey, in which participants reported improvements in health, wellbeing, endurance and sitting balance. Wandercraft expects Eve could become eligible for Medicare reimbursement within 60 to 90 days of clearance, which would put it within reach of more people. Reporting and analysis from sources such as IEEE Spectrum track the same developments, and specialists following self-balancing exoskeleton Eve say the direction is now consistent across independent lines of evidence.
The Wider Context
Adoption of self-balancing exoskeleton Eve follows a familiar pattern with an unfamiliar speed. Early users tolerate rough edges in exchange for advantage, mainstream users arrive when the tool disappears into existing workflows, and the market consolidates around whoever made that transition feel effortless. Vendors are racing less on raw performance now than on integration, support and trust.
What Happens Next
The realistic forecast for self-balancing exoskeleton Eve is steady integration rather than sudden replacement: embedded in products people already use, improving in increments, and regulated in proportion to its reach. The companies and institutions that plan on that basis, training staff and redesigning processes instead of chasing launches, are the ones the adoption data tends to vindicate. You can follow related developments in our coverage of technology.
It is also worth remembering how quickly the picture in this area has changed before. Positions that looked settled a few years ago have been revised as new data arrived, and the same humility is appropriate now. The strongest coverage of this subject, and the most useful advice, tends to come from sources that update their views openly when the facts move, rather than defending an earlier position long after it has stopped fitting the evidence available.